Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

ClinicalTrials.gov ID: NCT02842086

Public ClinicalTrials.gov record NCT02842086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.

Study identification

NCT ID: NCT02842086
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Gilead Sciences; Industry
Enrollment: 5,399 participants

Conditions and interventions

Conditions

Pre-Exposure Prophylaxis of HIV-1 Infection

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2, 2016 (Actual)
Primary completion: Jan 31, 2019 (Actual)
Completion: Jul 29, 2026 (Actual)
Last update posted: Sep 8, 2026

2016 – 2026

United States locations

U.S. sites: 54
U.S. states: 21
U.S. cities: 41

Facility	City	State	ZIP	Site status
Not listed	Beverly Hills	California	90211	—
Not listed	Los Angeles	California	90036	—
Not listed	Los Angeles	California	90069	—
Not listed	Newport Beach	California	92663	—
Not listed	Oakland	California	94609	—
Not listed	Sacramento	California	95817	—
Not listed	Sacramento	California	95825	—
Not listed	San Diego	California	92103	—
Not listed	San Francisco	California	94102	—
Not listed	San Francisco	California	94103	—
Not listed	San Francisco	California	94118	—
Not listed	Torrance	California	90502	—
Not listed	Aurora	Colorado	80045	—
Not listed	Denver	Colorado	80209	—
Not listed	New Haven	Connecticut	06510	—
Not listed	Washington D.C.	District of Columbia	20009	—
Not listed	Washington D.C.	District of Columbia	20036	—
Not listed	Fort Lauderdale	Florida	33308	—
Not listed	Fort Lauderdale	Florida	33316	—
Not listed	Ft. Pierce	Florida	34982	—
Not listed	Miami	Florida	33136	—
Not listed	Orlando	Florida	32803	—
Not listed	Pensacola	Florida	32504	—
Not listed	West Palm Beach	Florida	33407	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Atlanta	Georgia	30309	—
Not listed	Atlanta	Georgia	30312	—
Not listed	Macon	Georgia	31201	—
Not listed	Chicago	Illinois	60612	—
Not listed	Chicago	Illinois	60613	—
Not listed	New Orleans	Louisiana	70119	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Springfield	Massachusetts	01105	—
Not listed	Berkley	Michigan	48072	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55415	—
Not listed	Las Vegas	Nevada	89104	—
Not listed	Somers Point	New Jersey	08244	—
Not listed	Santa Fe	New Mexico	87505	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10032	—
Not listed	New York	New York	10037	—
Not listed	The Bronx	New York	10467	—
Not listed	Chapel Hill	North Carolina	27599-7215	—
Not listed	Huntersville	North Carolina	28078	—
Not listed	Cleveland	Ohio	44109	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Austin	Texas	78705	—
Not listed	Dallas	Texas	75208	—
Not listed	Dallas	Texas	75246	—
Not listed	Houston	Texas	77098	—
Not listed	Seattle	Washington	98101	—
Not listed	Seattle	Washington	98104	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02842086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 8, 2026 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02842086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →